iBio, Inc. 8-K

What Happened

• iBio, Inc. announced its financial results for the quarter ended March 31, 2026 in a press release issued and furnished on May 12, 2026. The company filed a Current Report on Form 8-K (Item 2.02) to disclose these quarterly results; the press release is attached as Exhibit 99.1 to the filing.

Key Details

• Filing date: May 12, 2026 (Form 8-K, Item 2.02 — Results of Operations and Financial Condition).
• Period covered: Quarter ended March 31, 2026 (Q1 2026).
• Disclosure format: Results announced via press release furnished as Exhibit 99.1 to the 8-K.
• Administrative: Form 8-K signed by Marc A. Banjak, Chief Legal Officer.

Why It Matters

• This 8-K notifies investors that iBio has publicly released its quarterly earnings and other financial information; the Form 8-K itself does not include the detailed numbers in-line, so investors should review the press release (Exhibit 99.1) for revenue, earnings, cash position, and other metrics.
• Quarterly results can affect share price and investor expectations about near-term performance; check the press release and subsequent 10-Q (if filed) for full financial statements and management commentary.